ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near London, England, GBR:

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

London, United Kingdom and 66 other locations

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Loncastuximab Tesirine
Drug: Polatuzumab Vedotin

Phase 1

ADC Therapeutics

London, United Kingdom and 27 other locations

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Enrolling
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

London, Surrey, United Kingdom and 73 other locations

in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).Part 2: Cohort Expansion. The...

Enrolling
Non-Hodgkin Lymphoma
Relapsed Solid Tumors
Drug: KB-0742

Phase 1, Phase 2

Kronos Bio

London, United Kingdom and 25 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

London, United Kingdom and 55 other locations

The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The ma...

Enrolling
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Drug: JNJ-90009530

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

London, United Kingdom and 14 other locations

study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non...

Active, not recruiting
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Drug: Capivasertib

Phase 2

AstraZeneca
AstraZeneca

Sutton, United Kingdom and 16 other locations

(CAR) targeting CD19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non- ...

Enrolling
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Biological: AUTO1

Phase 1

Autolus

London, United Kingdom and 5 other locations

additional open-label imaging feasibility sub-study using a tracer in adult participants with relpased/refractory B-cell non-Hodgkin...

Active, not recruiting
Non-Hodgkins Lymphoma
Drug: Polatuzumab Vedotin
Drug: Tocilizumab

Phase 1, Phase 2

Roche
Roche

London, United Kingdom and 19 other locations

targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with relapsed or refractory B-Cell non- ...

Enrolling
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Biological: JNJ-90014496

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

London, United Kingdom and 19 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems